Rituximab-HyperCVAD (R-HCVAD) Alternating With Rituximab-Methotrexate-Cytarabine- (R-MC) in Newly Diagnosed Patients With Diffuse Large B-Cell Lymphoma With MYC-Rearrangement.

NCT01854372 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Conditions

Newly Diagnosed Diffuse Large B-Cell Lymphoma
Intermediate (Burkitt-Like) Lymphoma

Interventions

DRUG: R-HCVAD and R-MC

Sponsor

The University of Texas Health Science Center at San Antonio